Above Tire Fix-It Shop Glycart Makes Roche Leukemia Drug
This article is for subscribers only.
Roche Holding AG is cooking up a next generation of cancer-killing drugs above a suburban Swiss tire-repair store.
The labs in an industrial corner of Zurich are the birthplace of GA101, a blood-cancer medicine from Roche’s Glycart biotechnology unit that was approved in the U.S. last month under the brand name Gazyva. The drug is heir apparent to leukemia treatment Rituxan, Roche’s top seller last year.